Abstract
Sexual dysfunction is frequently encountered in hypertensive patients. Available data indicates that sexual dysfunction is more frequent in treated than in untreated patients, generating the hypothesis that antihypertensive therapy might be associated with sexual dysfunction. Several lines of evidence suggest that differences between antihypertensive drugs exist regarding their effects on sexual function. Older antihypertensive drugs (diuretics, beta blockers) exert detrimental effects on erectile function whereas newer drugs (nebivolol, angiotensin receptor blockers) have neutral or even beneficial effects. Phosphodiesterase (PDE)-5 inhibitors are effective in hypertensive patients and can be safely administered even when multidrug regimes are used. Precautions need to be taken with alpha blockers or patients with uncontrolled high-risk hypertension, while co-administration with nitrates is contraindicated.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance
• Manolis A, Doumas M. Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications. J Hypertens. 2008;26:2074–84. A comprehensive review revealing the association of arterial hypertension and sexual dysfunction, and its impact on life quality..
Doumas M, Douma S. Sexual dysfunction in essential hypertension: myth or reality? J Clin Hypertens. 2006;8:269–74.
Doumas M, Douma S. The effect of antihypertensive drugs on erectile function: a proposed management algorithm. J Clin Hypertens. 2006;8:359–64.
Manolis A, Doumas M. Hypertension and sexual dysfunction. Arch Med Sci. 2009;5:S337–50.
Douma S, Doumas M, Tsakiris A, Zamboulis C. Male and female sexual dysfunction: Is hypertension an innocent bystander or a major contributor? Rev Bras Hypertens. 2007;14:139–47.
Doumas M, Tsakiris A, Douma S, et al. Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared with normotensive subjects. J Androl. 2006;27:469–77.
Doumas M, Tsiodras S, Tsakiris A, et al. Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens. 2006;24:2387–92.
Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.
Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible consequences. Br J Urol Int. 1999;84:50–6.
Manolis AJ, Doumas M, Viigimaa M, Narkiewitz K. Hypertension and sexual dysfunction. European Society of Hypertension Scientific Newsletter: Update on Hypertension Management 2007;8.
Manolis AJ, Doumas M, Viigimaa M, Narkiewitz K. Hypertension and sexual dysfunction. European Society of Hypertension Scientific Newsletter: Update on Hypertension Management 2011;32.
•• Viigimaa M, Doumas M, Vlachopoulos C, et al. European Society of Hypertension Working Group on Sexual Dysfunction. Hypertension and sexual dysfunction: time to act. J Hypertens. 2011;29:403–7. doi:403. A position paper from the European Society of Hypertension, highlighting the causes of sexual dysfunction in patients with arterial hypertension, and the significance of this entity.
• Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291:2978–84. The first randomized study to evaluate the effects of lifestyle modification on erectile function. A significant improvement of erectile function was observed with weight reduction.
Wing RR, Rosen RC, Fava JL, et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the look AHEAD trial. J Sex Med. 2010;7:156–65.
Dallal RM, Chernoff A, O’Leary MP, et al. Sexual dysfunction is common in the morbidly obese male and improves after gastric bypass surgery. J Am Coll Surg. 2008;207:859–64.
Esposito K, Ciotola M, Giugliano F, et al. Mediterranean diet improves sexual function in women with the metabolic syndrome. Int J Impot Res. 2007;19:486–91.
Esposito K, Ciotola M, Giugliano F, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res. 2006;18:405–10.
Hannan JL, Maio MT, Komolova M, Adams MA. Beneficial impact of exercise and obesity interventions on erectile function and its risk factors. J Sex Med. 2009;6:S254–61.
Lamina S, Okoye CG, Dagogo TT. Therapeutic effect of an interval exercise training program in the management of erectile dysfunction in hypertensive patients. J Clin Hypertens. 2009;11:125–9.
Claudino M, Delbin M, Franco-Penteado C, et al. Exercise training ameliorates the impairment of endothelial and nitrergic corpus cavernosum responses in diabetic rats. Life Sci. 2011;88:272–7.
Doumas M, Anyfanti P, Triantafyllou A. Management of erectile dysfunction: do not forget hypertension. Arch Intern Med. 2012;172:597–8.
•• Gupta B, Murad H, Clifton M, et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction. Arch Intern Med. 2011;171:1797–803. An important meta-analysis of studies assessing the effect of lifestyle modification on erectile function..
Helmy M, Senbel A. Evaluation of vitamin E in the treatment of erectile dysfunction in aged rats. Life Sci. 2012;90:489–94.
Cormio L, Siati M, Lorusso F, et al. Oral L-citrulline supplementation improves erection hardness in men with mild erectile dysfunction. Urology. 2011;77:119–22.
Ernst E, Posadzki P, Lee M. Complementary and alternative medicine (CAM) for sexual dysfunction and erectile dysfunction in older men and women: An overview of systematic reviews. Maturitas. 2011;70:37–41.
Toblli J, Stella I, Néstor Mazza O, Ferder L, Inserra F. Protection of cavernous tissue in male spontaneously hypertensive rats. Beyond blood pressure control. Am J Hypertens. 2004;17:516–22.
Toblli JE, Cao G, Casas G, Mazza ON. In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats. Am J Hypertens. 2006;19:1226–32.
Cordero A, Bertomeu-Martinez V, Mazon P, et al. Erectile dysfunction in high-risk hypertensive patients treated with beta-blockers agents. Cardiovasc Ther. 2010;28:15–22.
Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens. 2001;14:27–31.
Fogari R, Preti P, Derosa G, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol. 2001;58:177–80.
Fogari R, Zoppi A, Corradi L, et al. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens. 1998;11:1244–7.
Williams GH, Croog SH, Levine S, et al. Impact of antihypertensive therapy on quality of life: effect of hydrochlorothiazide. J Hypertens. 1987;5:S29–35.
Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351–7.
Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol. 2007;34:327–31. A randomized study which unveils the beneficial effects of nebivolol on sexual function compared to older beta blockers..
Grimm RH, Grandits GA, Prineas RJ, Mc Donald RH, Lewis CE, Flack JM, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women: Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;29:8–14.
Medical Research Council Working Party on mild to moderate hypertension, report of 1981. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet. 1981;2:539–543.
Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM study. Ann Intern Med. 1991;114:613–20.
Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the antihypertensive treatment and lipid profile in a north of Sweden efficacy evaluation (ALPINE study). J Hypertens. 2003;21:1563–74.
Bechara AJ, Cao G, Casabé AR, Romano SV, Toblli JE. Morphological modifications in clitoris and vagina in spontaneously hypertensive rats. Int J Impot Res. 2003;15:166–72.
Fogari R, Preti P, Zoppi A, et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens. 2004;17:77–81.
• Ma R, Yu J, Xu D, et al. Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. J Hypertens. 2011;30:210–6. An important randomized study of combination therapy in hypertensive women, which shows that ARBs exert beneficial effects on female sexual function compared to beta blockers when either drug is combined with calcium antagonists..
Doumas M, Anyfanti P, Lazaridis N. Effects of antihypertensive therapy on female sexual dysfunction: clinically meaningful? J Hypertens 2012; In press.
Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005;96:313–21.
Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press. 2003;12:S29–34.
Della Chiesa A, Pfifner D, Meier B, et al. Sexual activity in hypertensive men. J Hum Hypertens. 2003;17:515–21.
Llisterri JL, Lozano Vidal JV, Aznar Vicente J, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci. 2001;321:336–41.
Doumas M, Tsakiris A, Douma S, et al. Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian J Androl. 2006;8:177–82.
Baumhakel M, Schlimmer N, Bohm M. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res. 2008;20:493–500.
Douma S, Doumas M, Petidis K, Triantafyllou A, Zamboulis C. Beta blockers and sexual dysfunction: bad guys – good guys. In: Beta Blockers: New Research – editors: Momoka Endo and Narami Matsumoto. Nova Science Publishers Inc. 2008;1–13.
Baumhakel M, Schimmer N, Kratz M, et al. Cardiovascular risk, drugs and erectile function – a systematic analysis. Int J Clin Pract. 2011;65:289–98.
Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24:1928–32.
Cocco G. Erectile dysfunction after therapy with metoprolol: the Hawthorne effect. Cardiology. 2009;112:174–7.
•• Böhm M, Baumhäkel M, Teo K, et al. ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile Dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANCEND) Trials. Circulation. 2010;121:1439–46. The first substudy of a large, randomized trial evaluating the effect of ARBs on erectile function. It was found that erectile dysfunction is a strong predictor of cardiovascular events and that ARBs do not have any significant effect on erectile function. It has to be taken into account that ARBs were used on top of previous multidrug antihypertensive treatment..
Ballard SA, Gingell CJ, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 1998;159:2164–71.
Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8:47–52.
Maggi M, Filippi S, Ledda F, et al. Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. Eur J Endocrinol. 2000;143:143–54.
Jackson G, Benjamin N, Jackson N, et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol. 1999;83:13C–20C.
Montague DK, Jarow JP, Broderick GA, et al. Erectile Dysfunction Guideline Update Panel. The management of erectile dysfunction: an AUA update. J Urol. 2005;174:230–9.
Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J. 2002;4:H32–47.
Zusman RM, Prisant LM, Brown MJ. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens. 2000;18(12):1865–9.
Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol. 2003;92:37M–46M.
van Ahlen H, Wahle K, Kupper W, et al. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med. 2005;2:856–64.
Pickering TG, Shepherd AM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens. 2004;17:1135–42.
McLaughlin T, Harnett J, Burhani S, Scott B. Evaluation of erectile dysfunction therapy in patients previously nonadherent to long-term medications: a retrospective analysis of prescription claims. Am J Ther. 2005;12:605–11.
Scranton RE, Lawler E, Botteman M, et al. Effect of treating erectile dysfunction on management of systolic hypertension. Am J Cardiol. 2007;100:459–63.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Manolis, A., Doumas, M. Antihypertensive Treatment and Sexual Dysfunction. Curr Hypertens Rep 14, 285–292 (2012). https://doi.org/10.1007/s11906-012-0276-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-012-0276-5